Company profile: Lyell
1.1 - Company Overview
Company description
- Provider of cellular immunotherapies and T-cell reprogramming for solid tumors, including CAR T-cell and TIL therapies. Offerings include Epi-R to generate stem-like T cells, Stim-R to optimize delivery of immune-activating molecules, and Rejuvenation Technology to reduce epigenetic age and enhance proliferation and antitumor activity.
Products and services
- T-Cell Reprogramming Technologies: Lyell engineers genetic and epigenetic T-cell reprogramming, custom-engineered to delay exhaustion and boost antitumor activity in solid tumors, enhancing functionality and durability
- Chimeric Antigen Receptor (CAR) T-Cell Therapy: Lyell produces biomarker-guided CAR T cells that recognize and kill cancer cells in solid tumors, architected to target specific tumor-associated markers for precise cytotoxicity
- Tumor-Infiltrating Lymphocyte (TIL) Therapy: Lyell constructs tumor-derived TIL products by collecting and expanding intratumoral T cells to intensify infiltration and cytotoxic killing of cancer cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lyell
Ideaya Biosciences
HQ: United States
Website
- Description: Provider of oncology therapeutics for genetically defined cancers, with clinical-stage programs including darovasertib (IDE196) for GNAQ/GNA11-mutant tumors (metastatic uveal melanoma), IDE397 targeting MAT2A for MTAP-deleted tumors, and IDE161 for HRD tumors. Also offers synthetic lethality target identification with UCSD (CRISPR screens) and biomarker and translational research with the Broad Institute.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ideaya Biosciences company profile →
Kineta
HQ: United States
Website
- Description: Provider of biotechnology discovery and development focused on antiviral therapies and immune-modulating drugs for RNA viruses—including hepatitis C, influenza, West Nile virus, and the common cold—and aiming to develop therapeutics for autoimmune disease, viral disease, and chronic pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kineta company profile →
Calidi Biotherapeutics
HQ: United States
Website
- Description: Provider of clinical-stage cancer immunotherapies based on stem cell-delivered oncolytic viruses. Programs include NeuroNova (neural stem cells + oncolytic adenovirus) for glioblastoma; SuperNova (adipose-derived mesenchymal stem cells + oncolytic vaccinia) for advanced solid tumors; RTNova, a systemic enveloped oncolytic virotherapy; CLD-101 in Phase 1 for recurrent high-grade glioma; and CLD-201, a cell-based virotherapy planned for Phase 1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calidi Biotherapeutics company profile →
Agalimmune
HQ: United States
Website
- Description: Provider of immunotherapeutic technology, licensing the Alphaject technology from the University of Massachusetts Medical School; located in London, UK and California, USA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agalimmune company profile →
GT Biopharma
HQ: United States
Website
- Description: Provider of TriKE immunotherapy technology that bridges natural killer cells to cancer cells to boost anti-tumor responses. Pipeline includes GTB-3550 for CD33+ leukemias (AML, high-risk MDS), GTB-3650 using camelid nanobodies for CD33+ leukemias, and GTB-5550, GTB-4550, GTB-6550 for B7H3, PD-L1, and HER2 positive solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GT Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lyell
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lyell
2.2 - Growth funds investing in similar companies to Lyell
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lyell
4.2 - Public trading comparable groups for Lyell
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →